SCHEMBL2657124

SCHEMBL2657124

CCN1Cc2nc3c(-c4ccc(F)cc4OC)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 5/20 0.41
▸ UGCG Q16739 2/20 0.38
▸ GABRG2 P18507 2/20 0.36
▸ GABRB3 P28472 2/20 0.36
▸ GABRA2 P47869 2/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ CRHR1 P34998 1/20 0.36
▸ PDE6C P51160 1/20 0.35
▸ P2RX7 Q99572 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ SCN9A Q15858 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921356 0.93 GABRG2 (0.37) PDE5AUGCGGABRG2GABRB3GABRA2
SCHEMBL2655165 0.93 PDE5A (0.43) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2655510 0.91 PDE5A (0.41) PDE5AUGCGGABRG2GABRB3GABRA2
SCHEMBL2661947 0.90 CRHR1 (0.46) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2660724 0.88 MAPT (0.39) PDE5ACRHR1GRIN1GRIN2B
SCHEMBL2661396 0.87 PDE5A (0.43) PDE5AUGCGGABRG2GABRB3GABRA2
SCHEMBL4919706 0.87 GABRA1 (0.49) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2661407 0.87 PDE5A (0.41) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL4916122 0.85 GABRG2 (0.39) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL4924490 0.85 PDE5A (0.40) PDE5AGABRG2GABRB3GABRA2GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF PDE5A 742/4885UGCG 2572/4885GABRG2 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback